Sarepta Therapeutics Shares Face Persistent Analyst Doubt Despite Upward Earnings Revision

Mixed Signals from Research Firms

Sarepta Therapeutics shares closed Friday’s trading session down 2.9 percent at $17.39, a decline that occurred despite a positive earnings forecast adjustment from Leerink Partners.

While Leerink Partners upgraded its third-quarter 2025 EPS estimate from -$1.08 to -$0.70, the firm maintained its “Hold” rating on the biopharmaceutical company. The broader analyst consensus, comprising seven research firms, also showed modest improvement, moving from -$0.37 to -$0.31 per share.

The overall sentiment toward Sarepta remains cautious. Among the 29 analyst firms covering the stock, recommendations include eight “Buy” ratings, fifteen “Hold” positions, and six “Sell” advisories. Price targets reflect significant divergence, ranging from $30.50 to $68.59 per share.

Regulatory Environment and Strategic Shifts